disorders

Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

February 04, 2026 09:35 ET  | Source: Adial Pharmaceuticals, Inc GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial…

4 days ago

Manipal Hospitals Enhances Movement and Confidence Through Awareness on Movement Disorders

BENGALURU, India, Dec. 8, 2025 /PRNewswire/ -- Parkinson's disease often begins far more quietly than many people realise. Early indicators…

2 months ago

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinsons Disease and Movement Disorders

– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102…

4 months ago